Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer: patient selection and special considerations

Overview of attention for article published in OncoTargets and therapy, August 2017

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (63rd percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

twitter: 1 X user

patent: 1 patent

Citations

dimensions_citation: 9 Dimensions

Readers on

mendeley: 28 Mendeley

Summary X Patents Dimensions citations

So far, Altmetric has seen 1 patent that references this research output.

CABAZITAXEL IN MCRPC PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL AND WHO FAILED A PRIOR…

Application EP-3797834-A1

European Patent Office